Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

This study is ongoing, but not recruiting participants.
Celgene Corporation
Information provided by (Responsible Party):
Michaela Liedtke, Stanford University Identifier:
First received: May 16, 2011
Last updated: January 11, 2017
Last verified: January 2017
To assess if amrubicin is safe and useful for patients with multiple myeloma requiring additional treatment.

Condition Intervention Phase
Multiple Myeloma
Drug: Amrubicin
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Aspirin
Drug: Pegfilgrastim
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1-2 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Response Rates After Amrubicin + Lenalidomide + Dexamethasone to Treat Relapsed / Refractory Multiple Myeloma [ Time Frame: 12 weeks ]
    Therapeutic response rates in relapsed / refractory multiple myeloma after treatment with the combination of amrubicin, lenalidomide, and dexamethasone were measured as Complete Response (CR); Very Good Partial Response (VGPR) and Partial Response, were assessed after treatment, and were collectively expressed as the combined rate of Complete Response (CR) and Very Good Partial Response (VGPR), and the Overall Response Rate (ORR, the sum of CR + VGPR + PR). Response was assessed based on the modified International Myeloma Working Group Uniform Response Criteria.

Secondary Outcome Measures:
  • Duration of Response (DOR) [ Time Frame: 140 days ]
  • Progression-free Survival (PFS) [ Time Frame: 9 months ]
  • Time-to-next Treatment [ Time Frame: 9 months ]

Enrollment: 14
Study Start Date: August 2011
Estimated Study Completion Date: July 2017
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Amrubicin + Lenalidomide + Dexamethasone

Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.

Concurrent therapeutic medications:

  • Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
  • Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)

Other drugs:

  • Aspirin: 81 or 325 mg daily oral
  • Pegfilgrastim subcutaneous on Day 2
Drug: Amrubicin
40, 60, or 80 mg/m2 intravenous (IV)
Other Name: SM-5887
Drug: Lenalidomide
15 mg daily by mouth
Other Names:
  • CC-5013
  • Revlimid
Drug: Dexamethasone
40 mg weekly by mouth
Other Names:
  • Decadron
  • Dexamethasone Intensol
  • Dexpak Taperpak
Drug: Aspirin
81 or 325 mg daily by mouth
Other Name: acetylsalicylic acid
Drug: Pegfilgrastim
6 mg subcutaneous on Day 2
Other Names:
  • Neulasta

Detailed Description:


  • Establish the maximum tolerated dose (MTD) and toxicity profile for the combination of amrubicin with lenalidomide and dexamethasone in previously treated adult patients with multiple myeloma during Phase I
  • Determine the combined rate of complete response (CR) and very good partial response (VGPR) for this combination in this population as defined by the International Myeloma Working Group Uniform Response Criteria (IMWGURC)


  • Determine the overall response rate (CR, VGPR and PR)
  • Assess additional evidence of ant-tumor activity as measured by duration of response (DOR), progression-free survival (PFS), time to tumor progression (TTP), and overall survival (OS)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relapsed or refractory multiple myeloma that has progressed following at least 1 prior therapy.
  • Measurable disease defined as one of the following:

    • Serum M-protein ≥ 1 g/dL
    • Urine M-protein ≥ 200 mg/24 hours
  • Received at least 1 prior line of systemic treatment that may have included lenalidomide and/or an anthracycline.
  • No cytotoxic chemotherapy within 4 weeks prior to first dose of amrubicin. This interval may be reduced to 14 days for thalidomide, lenalidomide, bortezomib or corticosteroids, provided other entry criteria are met.
  • Age ≥ 18 at the time of consent.
  • Life expectancy of more than ≥ 3 months.
  • No known central nervous system involvement by myeloma.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 at study registration during phase 1. Once safety is confirmed, ECOG performance status 0 to 2 at study registration during phase 2.
  • No poorly-controlled intercurrent illness.
  • Platelets > 100 x 10^9/L
  • Hemoglobin > 8.0g/dL
  • Absolute neutrophil count (ANC) >1.5 x 10^9/L
  • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 x ULN
  • Calculated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula.
  • Left ventricular ejection fraction (LVEF) ≥ 50% by Echocardiogram (ECHO) or multiple gate acquisition scan (MUGA)
  • All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the Requirements of RevAssist.
  • Disease-free of prior malignancies for ≥ 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 U/mL within 10 to 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing.
  • Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Able to take aspirin (81 or ≥ 25 mg) daily as prophylactic anticoagulation. Patients intolerant to aspirin may use warfarin or low molecular weight heparin (LMWH). Patients with previous thromboembolic event on lenalidomide or thalidomide may be started on warfarin or LMWH. Patients already taking warfarin or LMWH do not require additional aspirin..
  • Lactating females must agree not to breast-feed while taking lenalidomide

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  • Pregnant or breastfeeding females.
  • Any concurrent severe or uncontrolled medical disease which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Use of any other experimental drug or therapy within 28 days of first dose of amrubicin.
  • Known hypersensitivity to thalidomide or lenalidomide.
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  • LVEF ≤ 50%.
  • Concurrent use of other anti-cancer agents or treatments.
  • Known positive for HIV, or infectious hepatitis, type B or C.
  • Cranial radiotherapy ≤ 21 days prior to first dose of amrubicin; radiotherapy to all other areas ≤ 7 days prior to first dose of amrubicin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01355705

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Michaela Liedtke
Celgene Corporation
Principal Investigator: Michaela Liedtke Stanford University
  More Information

Responsible Party: Michaela Liedtke, Assistant Professor Medicine/Hematology, Stanford University Identifier: NCT01355705     History of Changes
Other Study ID Numbers: IRB-19092
AR_MM_PI_007 ( Other Identifier: Celgene Corporation )
SU-05062011-7711 ( Other Identifier: Stanford University )
HEMMYL0018 ( Other Identifier: OnCore )
Study First Received: May 16, 2011
Results First Received: January 11, 2017
Last Updated: January 11, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones processed this record on May 23, 2017